TICKERNERD
Menu
ACHACHHealthcare · Medical Distribution

ACH Stock Forecast: Accendra Health, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$3.41
+10.36% on the day

The 6 Wall Street analysts covering Accendra Health, Inc. hold a median 12-month price target of $4.5 — +32.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 42 of 100 as at 1 Aug 2026 — in the lower half.

Market cap
$236.6M
Ticker Nerd rank
42 / 100
Median analyst target
$4.50
Analysts covering
6
Total return, dividends reinvested
1W
+5.9%
1M
−5.0%
YTD
+21.8%
1Y
−48.1%
From 52W high
−51.9%
From 52W low
+78.5%
$1.91
$7.09
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ACH stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Accendra Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
42 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Issuance
93
Value
72
Accruals
70
Size
65
Quality
62
Revisions
28
Momentum
20
Volatility
16
Growth
10

Issuance (93): The share count has been shrinking and the company is not leaning on new borrowing.

Growth (10): Sales and profits are flat, shrinking, or growing more slowly than they were.

The rank is the raw material. Whether the rules would actually own Accendra Health, Inc. — and when they’d sell — is the membership.

Wall Street

ACH stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ACH, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$3.00$4.00$5.00$6.00$7.00Oct 25Jan 26Apr 26Jul 26ACHHigh $6.00Median $4.50Low $2.70

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says6 analysts
2 Buy2 Hold2 Sell
Low $2.70Median $4.50High $6.00

The green dot is the last close — the median target sits +32.0% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
24 July 2026CitigroupMaintainsBuy$5.00 → $4.50
12 May 2026BairdMaintainsOutperform—
12 May 2026BairdMaintainsOutperform$5.00 → $6.00
12 May 2026CitigroupMaintainsBuy$3.25 → $5.00
12 May 2026CitigroupMaintainsBuy—
12 May 2026UBSMaintainsNeutral$3.00 → $4.50
12 May 2026UBSMaintainsNeutral—
20 Feb 2026Leerink PartnersMaintainsMarket Perform—
9 Jan 2026CitigroupMaintainsBuy—
3 Nov 2025UBSDowngradeNeutral—
27 Aug 2025JP MorganMaintainsUnderweight—
13 Aug 2025UBSMaintainsBuy—
12 Aug 2025B of A SecuritiesMaintainsUnderperform—
12 Aug 2025BairdMaintainsOutperform—
12 Aug 2025CitigroupMaintainsBuy—
25 Aug 2022Goldman SachsUpgradeNeutral—
7 Jan 2020Goldman SachsDowngradeSell—
3 Jan 2020MacquarieInitiatesOutperform—
15 Nov 2019CLSAUpgradeOutperform—
30 Apr 2019Credit SuisseDowngradeUnderperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

ACH analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−42.7%
Analysts raising
0
Analysts cutting
6
Fundamentals

Accendra Health, Inc. (ACH) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
8.8×

Cheaper than 61% of US stocks

Price / sales
0.1×

Cheaper than 97% of US stocks

Price / book
−0.5×

Cheaper than 93% of US stocks

EV / EBITDA
6.4×

Cheaper than 51% of US stocks

Growth & margins
Revenue growth (YoY)
−6.8%

Higher than 19% of US stocks

Earnings growth (YoY)
−76.1%

Higher than 5% of US stocks

Gross margin
44.3%

Higher than 57% of US stocks

Operating margin
−1.0%

Higher than 34% of US stocks

Net margin
−39.8%

Higher than 11% of US stocks

Returns & dividend
Return on equity
−198.4%

Higher than 7% of US stocks

Return on assets
1.6%

Higher than 56% of US stocks

Dividend yield
0.4%

Higher than 7% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ACH vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Distribution
CompanyMarket capTKN rank
ACHAccendra Health, Inc.$236.6M
42
COSMCosmos Health, Inc.$12.9M
23
MGNXMacroGenics, Inc.*$234.5M
78
SIGASIGA Technologies, Inc.*$234.3M
65
OBIOOrchestra Biomed Holdings, Inc.*$232.9M
51
TTRXTurn Therapeutics, Inc.*$246.2M
15
RXSTRxSight, Inc.*$248.8M
53

* Nearest Healthcare names by size — few medical distribution companies of this scale trade in the US universe.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ACH appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest ACH news & analysis

Accendra Health Announces Second Quarter 2026 Earnings Release Date and Conference Call

Business Wire · 27 July 2026neutral

Accendra Health, Inc. announced it will release its second quarter 2026 financial results on August 10, 2026, before market open, followed by a conference call for investors and analysts at 8:00 a.m. EDT that same day.

Why it matters — The announcement provides ACH stakeholders with the date and access details for the company's quarterly earnings report and management discussion of results.

FAQ

Frequently asked questions about ACH stock

What is the ACH stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Accendra Health, Inc. have a median 12-month price target of $4.5, with estimates ranging from $2.7 to $6. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ACH stock a buy right now?

Of the 6 analysts covering Accendra Health, Inc., 2 rate it a Buy, 2 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Accendra Health, Inc. 42 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ACH?

As at 1 Aug 2026, Accendra Health, Inc. ranks 42 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (93 of 100).

Will ACH stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +32.0% from the last close, and Ticker Nerd's factor model ranks Accendra Health, Inc. 42 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ACH stock forecast for 2030?

No analyst covering Accendra Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ACH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2.7 to $6 over the next 12 months.

How has ACH stock performed over the past year?

Accendra Health, Inc. returned -48.1% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Accendra Health, Inc. do?

Accendra Health, Inc. is a leading nationwide provider of products, technology, and services that support health beyond the hospital for millions of people annually.

What is the latest news on ACH?

The most recent item we track (Business Wire, 27 July 2026): "Accendra Health Announces Second Quarter 2026 Earnings Release Date and Conference Call". Accendra Health, Inc. announced it will release its second quarter 2026 financial results on August 10, 2026, before market open, followed by a conference call for investors and analysts at 8:00 a.m. EDT that same day.

Company

About Accendra Health, Inc.

Accendra Health, Inc. is a leading nationwide provider of products, technology, and services that support health beyond the hospital for millions of people annually. The company connects patients, providers, and insurers through innovative solutions designed to promote better health outcomes and enhance quality of life for individuals managing chronic and complex conditions. Specializing in home-based care, Accendra Health offers a broad portfolio of essentials covering diabetes management, sleep health, wound care, respiratory support, urology, and ostomy needs. Backed by the expertise of its flagship Apria and Byram brands, it reimagines post-hospital care delivery with a focus on accessibility and efficacy. Founded in 1882 and headquartered in Richmond, Virginia, the company employs approximately 23,200 people and operates within the healthcare sector, particularly in health care distribution and patient direct services. Following a strategic divestiture of its former Products & Healthcare Services business at the end of 2025, Accendra Health continues to play a pivotal role in advancing home health solutions across the United States.

CEO Mr. Edward A. Pesicka · 6,500 employees · United States · https://www.accendrahealth.com